Shares of Hims & Hers Health Inc. (HIMS) surged 5.31% on Thursday, outperforming the broader market during the intraday trading session. The telehealth company's stock rallied amidst attention and buzz surrounding its provocative Super Bowl commercial criticizing weight-loss drug makers and the U.S. healthcare system.
While the controversial ad has prompted backlash from Senators Richard Durbin and Roger Marshall, who have requested an FDA investigation into potential misleading claims, it has also generated significant publicity for the company. Despite the controversy, Hims & Hers remains a highly rated stock in its industry group, with strong rankings for its Composite Rating, EPS Rating, and Relative Strength Rating.
Investors appear to be anticipating positive news from the company's upcoming earnings report scheduled for February 24th, which could provide further insight into its performance and outlook. The stock's rally highlights the market's interest in Hims & Hers and its ability to capitalize on the attention generated by its bold marketing strategy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。